Major Growth Driver Identified in 2025 Chemotherapy Induced Peripheral Neuropathy Treatment Market: Rising Cancer Prevalence Boosts Chemotherapy-Induced Peripheral Neuropathy Treatment Market

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for treating chemotherapy-induced peripheral neuropathy has seen robust growth in the recent past. The market size is predicted to expand from $1.66 billion in 2024 to $1.78 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. The remarkable growth during the historic period can be credited to advancements in chemotherapy, the expansion of cancer treatments, limited treatment alternatives, increased instances of cancer, and neurological research.

Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast: What's the Projected Valuation by 2029?
The market for treatment of chemotherapy-induced peripheral neuropathy is anticipated to witness significant expansion in the coming years, projecting a growth to $2.5 billion by 2029 with a compound annual growth rate (CAGR) of 8.9%. This escalation during the forecast period can be associated with the evolution of targeted therapies, neuroprotective drugs, comprehensive care pathways, patient-focused care models, and legislative backing. Key trends to observe during this period include the emergence of innovative drug compositions, non-medical interventions, therapies based on neuroplasticity, enduring survivorship support, and cognitive behavioral therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

What Are the Drivers Transforming the Chemotherapy Induced Peripheral Neuropathy Treatment Market?
The growing incidence of cancer worldwide is anticipated to boost the expansion of the market for treatment of chemotherapy-induced peripheral neuropathy. This disease is marked by the unregulated multiplication and dispersion of abnormal cells in the body. Certain chemotherapy medications used to treat cancer can possibly lead to chemotherapy-induced peripheral neuropathy as a side effect. The increase in cancer cases globally has prompted the growth of the market for chemotherapy-induced peripheral neuropathy treatment. To illustrate, the American Cancer Society, a U.S.-based national health organization committed to eradicating cancer, shared in a January 2023 report that the number of newly diagnosed liver cancer cases in American women jumped from 12,660 in 2022 to 13,230 in 2023. Consequently, the rising prevalence of cancer is fueling the expansion of the chemotherapy-induced peripheral neuropathy treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp

What Long-Term Trends Will Define the Future of the Chemotherapy Induced Peripheral Neuropathy Treatment Market?
The primary trend gaining traction in the treatment market for chemotherapy-induced peripheral neuropathy is product innovation. Dominant companies within this market are striving to introduce new products to enhance their competitive edge and maintain their standing. For example, in March 2023, AlgoTx, a firm on the clinical-stage specializing in managing complex pain, unveiled the FDA's approval for the Investigational New Drug Application (IND) for ATX01, their pioneering Phase 2 candidate. This novel treatment is designed for people suffering from erythromelalgia. Concurrently, the first patients have been selected in the ATX01 for the Pain of Chemotherapy (ACT) study specifically for chemotherapy-induced peripheral neuropathy (CIPN). The FDA has bestowed swift track designation to both programs.

Which Segments in the Chemotherapy Induced Peripheral Neuropathy Treatment Market Offer the Most Profit Potential?
The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented -

1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes
2) By Treatment: Medication, Therapy, Other Treatments
3) By Drug Type: Branded, Generic
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Research Institutes, Specialty Clinics

Subsegments:
1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine
2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine
4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10
5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11967&type=smp

Which Firms Dominate the Chemotherapy Induced Peripheral Neuropathy Treatment Market by Market Share and Revenue in 2025?
Major companies operating in the chemotherapy induced peripheral neuropathy treatment market include Hoffmann-La Roche Ltd., Midatech Pharma PLC, Novartis AG, Lee's Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, Eurofins Advinus, WEX Pharmaceuticals Inc., Asahi Kasei Corporation, MediciNova Inc., Solasia Pharma K.K., ESTEVE, ChromaDex Inc., Apollo Endosurgery Inc., REGENACY PHARMACEUTICALS INC., Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., WinSanTor Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation

Which Regions Offer the Highest Growth Potential in the Chemotherapy Induced Peripheral Neuropathy Treatment Market?
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2024. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11967

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Contact Us:
The Business Research Company
Europe - +44 7882 955267
Asia: +91 88972 63534
Americas - +1 310-496-7795
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.